» Articles » PMID: 15574779

Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Dec 3
PMID 15574779
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Although the RhoA and RhoC proteins comprise an important subset of the Rho GTPase family that have been implicated in invasive breast carcinomas, attributing specific functions to these individual members has been difficult. We have used a stable retroviral RNA interference approach to generate invasive breast carcinoma cells (SUM-159 cells) that lack either RhoA or RhoC expression. Analysis of these cells enabled us to deduce that RhoA impedes and RhoC stimulates invasion. Unexpectedly, this analysis also revealed a compensatory relationship between RhoA and RhoC at the level of both their expression and activation, and a reciprocal relationship between RhoA and Rac1 activation.

Citing Articles

Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage.

Alem D, Garcia-Lavina C, Garagorry F, Centurion D, Farias J, Pazos-Espinosa H Sci Rep. 2025; 15(1):4393.

PMID: 39910105 PMC: 11799152. DOI: 10.1038/s41598-025-88307-7.


MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity.

Boulton D, Hughes C, Vaira V, Del Gobbo A, Palleschi A, Locatelli M Cell Rep. 2024; 44(1):115120.

PMID: 39723893 PMC: 11837739. DOI: 10.1016/j.celrep.2024.115120.


Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.

Raghuram N, Temel E, Kawamata T, Kozma K, Loch A, Wang W Breast Cancer Res. 2024; 26(1):86.

PMID: 38807216 PMC: 11134842. DOI: 10.1186/s13058-024-01842-5.


Crumbs3 is expressed in oral squamous cell carcinomas and promotes cell migration and proliferation by affecting RhoA activity.

Yokoyama Y, Iioka H, Horii A, Kondo E Oncol Lett. 2022; 23(6):173.

PMID: 35497937 PMC: 9019858. DOI: 10.3892/ol.2022.13293.


OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.

Gugnoni M, Manzotti G, Vitale E, Sauta E, Torricelli F, Reggiani F J Exp Clin Cancer Res. 2022; 41(1):108.

PMID: 35337349 PMC: 8957195. DOI: 10.1186/s13046-022-02316-2.